Lazard Asset Management
AXSM icon

Lazard Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Lazard Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,163
Closed -$2.22M – 1959
2026
Q1 		$2.22M Sell
13,163
-247
-2% -$42.7K ﹤0.01% 842
2025
Q4 		$2.45M Sell
13,410
-8,427
-39% -$1.18M ﹤0.01% 786
2025
Q3 		$2.65M Sell
21,837
-7,456
-25% -$840K ﹤0.01% 768
2025
Q2 		$3.06M Buy
29,293
+44
+0.2% +$4.66K ﹤0.01% 873
2025
Q1 		$3.41M Sell
29,249
-508,420
-95% -$57.9M 0.01% 805
2024
Q4 		$45.5M Buy
537,669
+451,737
+526% +$41.5M 0.07% 208
2024
Q3 		$7.72M Buy
+85,932
New +$7.5M 0.01% 524

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Lazard Asset Management's AXSM Position: Q2 2026 in Review

Lazard Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 13,163 shares — an estimated $2.22M sold.

Lazard Asset Management first reported a position in AXSM in Q3 2024 and held it in 7 quarters. The position peaked at $45.5M in Q4 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Lazard Asset Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 13,163 Axsome Therapeutics shares in Q2 2026, an estimated $2.22M.
  • Lazard Asset Management first reported a position in Axsome Therapeutics in Q3 2024 and held it in 7 quarters.
  • Lazard Asset Management's Axsome Therapeutics position peaked at $45.5M in Q4 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.